Cited by 192Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsClinical practice guidelines implementation

The DOI matches its Crossref record; 222 of the 222 references it cites were found in a registry or an index.

ESC/EAS Guidelines for the management of dyslipidaemias

Catapano, Alberico L., Reiner, Željko, De Backer, Guy, Graham, Ian, Taskinen, Marja-Riitta, Wiklund, Olov, Agewall, Stefan, Alegria, Eduardo, Chapman, M. John, Durrington, Paul, Erdine, Serap, Halcox, Julian, Hobbs, Richard, Kjekshus, John, Perrone Filardi, Pasquale, Riccardi, Gabriele, Storey, Robert F., Wood, David·2011·Atherosclerosis

DOI 10.1016/j.atherosclerosis.2011.06.012

Open this paper in CoChat — free account

Integrity signals

Registry

Crossref · 10.1016/j.atherosclerosis.2011.06.012

Cites

222 of 222 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
Harmonizing the Metabolic Syndrome: A Joint Interim Statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity
Alberti, K. G. M. M., Eckel, R. H., Grundy, S. M., Zimmet, P. Z., Cleeman, J. I., Donato, K. A., Fruchart, J.-C., James, W. P. T., Loria, C. M., & Smith, S. C. (2009) · Circulation · doi:10.1161/circulationaha.109.192644 · Cited by 14,860
General Cardiovascular Risk Profile for Use in Primary Care: The Framingham Heart Study
D’Agostino, R. B., Vasan, R. S., Pencina, M. J., Wolf, P. A., Cobain, M., Massaro, J. M., & Kannel, W. B. (2008) · Circulation · doi:10.1161/circulationaha.107.699579 · Cited by 7,491
Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia
Shepherd, J., Cobbe, S. M., Ford, I., Isles, C. G., Lorimer, A. R., Macfarlane, P. W., McKillop, J. H., & Packard, C. J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199511163332001 · Cited by 7,449
The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
Sacks, F. M., Pfeffer, M. A., Moye, L. A., Rouleau, J. L., Rutherford, J. D., Cole, T. G., Brown, L., Warnica, J. W., Arnold, J. M. O., Wun, C.-C., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351401 · Cited by 7,439
MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09327-3 · Cited by 6,992
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials
Cholesterol Treatment Trialists' (CTT) Collaboration (2010) · The Lancet · doi:10.1016/s0140-6736(10)61350-5 · Cited by 6,550
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project
Conroy, R. (2003) · European Heart Journal · doi:10.1016/s0195-668x(03)00114-3 · Cited by 5,290
Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Primary Prevention of Acute Coronary Events With Lovastatin in Men and Women With Average Cholesterol Levels: Results of AFCAPS/TexCAPS
Downs, J. R., Clearfield, M., Weis, S., Whitney, E., Shapiro, D. R., Beere, P. A., Langendorfer, A., Stein, E. A., Kruyer, W., Gotto, Jr., et al. (1998) · JAMA · doi:10.1001/jama.279.20.1615 · Cited by 5,236
Helsinki Heart Study: Primary-Prevention Trial with Gemfibrozil in Middle-Aged Men with Dyslipidemia
Frick, M. H., Elo, O., Haapa, K., Heinonen, O. P., Heinsalmi, P., Helo, P., Huttunen, J. K., Kaitaniemi, P., Koskinen, P., Manninen, V., et al. (1987) · New England Journal of Medicine · doi:10.1056/nejm198711123172001 · Cited by 3,881
Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial
(1999) · The Lancet · doi:10.1016/s0140-6736(99)07072-5 · Cited by 3,812
Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial
Sever, P., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. J., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,790
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Self-citation
Intensive Lipid Lowering with Atorvastatin in Patients with Stable Coronary Disease
LaRosa, J. C., Grundy, S. M., Waters, D. D., Shear, C., Barter, P., Fruchart, J.-C., Gotto, A. M., Greten, H., Kastelein, J. J. P., Shepherd, J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050461 · Cited by 3,489
Gemfibrozil for the Secondary Prevention of Coronary Heart Disease in Men with Low Levels of High-Density Lipoprotein Cholesterol
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial
Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11600-x · Cited by 3,378
Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial
(2005) · The Lancet · doi:10.1016/s0140-6736(05)67667-2 · Cited by 3,284
Effects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139
Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
Pedersen, T. R. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.027 · Cited by 3,098
The Metabolic Syndrome and Cardiovascular Risk
Mottillo, S., Filion, K. B., Genest, J., Joseph, L., Pilote, L., Poirier, P., Rinfret, S., Schiffrin, E. L., & Eisenberg, M. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.05.034 · Cited by 3,009
High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061894 · Cited by 2,887
MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
(2003) · The Lancet · doi:10.1016/s0140-6736(03)13636-7 · Cited by 2,876
Effects of Combination Lipid Therapy in Type 2 Diabetes Mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001282 · Cited by 2,837
Effects of dietary fatty acids and carbohydrates on the ratio of serum total to HDL cholesterol and on serum lipids and apolipoproteins: a meta-analysis of 60 controlled trials
Mensink, R. P., Zock, P. L., Kester, A. D., & Katan, M. B. (2003) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/77.5.1146 · Cited by 2,811
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis
Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60527-3 · Cited by 2,516
Effects of Atorvastatin on Early Recurrent Ischemic Events in Acute Coronary Syndromes<SUBTITLE>The MIRACL Study: A Randomized Controlled Trial</SUBTITLE>
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
Sattar, N., Preiss, D., Murray, H. M., Welsh, P., Buckley, B. M., de Craen, A. J., Seshasai, S. R. K., McMurray, J. J., Freeman, D. J., Jukema, J. W., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(09)61965-6 · Cited by 2,436
Self-citation
Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation
Authors Task Force Members, de Werf, F. V., Bax, J. J., Betriu, A., Blomström‐Lundqvist, C., Crea, F., Falk, V., Filippatos, G. S., Fox, K. A. A., Huber, K., et al. (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn416 · Cited by 2,309
Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B
Brown, G., Albers, J. J., Fisher, L. D., Schaefer, S. M., Lin, J.-T., Kaplan, C., Zhao, X.-Q., Bisson, B. D., Fitzpatrick, V. F., & Dodge, H. T. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011083231901 · Cited by 2,159
Estrogen plus Progestin and the Risk of Coronary Heart Disease
Manson, J. E., Hsia, J., Johnson, K. C., Rossouw, J. E., Assaf, A. R., Lasser, N. L., Trevisan, M., Black, H. R., Heckbert, S. R., Detrano, R., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030808 · Cited by 2,065
Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Rosuvastatin and Cardiovascular Events in Patients Undergoing Hemodialysis
Fellström, B. C., Jardine, A. G., Schmieder, R. E., Holdaas, H., Bannister, K., Beutler, J., Chae, D.-W., Chevaile, A., Cobbe, S. M., Grönhagen-Riska, C., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810177 · Cited by 2,036
Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease
Brown, B. G., Zhao, X.-Q., Chait, A., Fisher, L. D., Cheung, M. C., Morse, J. S., Dowdy, A. A., Marino, E. K., Bolson, E. L., Alaupovic, P., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011090 · Cited by 1,979
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes
Bassand, J., Hamm, C. W., Ardissino, D., Boersma, E. H., Budaj, A., Fernández‐Avilés, F., Fox, K. A. A., Hasdai, D., Ohman, E. M., Wallentin, L. C., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm161 · Cited by 1,860
Cholesterol-lowering effects of dietary fiber: a meta-analysis
Brown, L., Rosner, B., Willett, W. W., & Sacks, F. M. (1999) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/69.1.30 · Cited by 1,857
Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin
Canner, P. L., Berge, K. G., Wenger, N. K., Stamler, J., Friedman, L., Prineas, R. J., & Friedewald, W. (1986) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(86)80293-5 · Cited by 1,824
Lipoprotein(a) as a cardiovascular risk factor: current status
Nordestgaard, B. G., Chapman, M. J., Ray, K., Borén, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., et al. (2010) · European Heart Journal · doi:10.1093/eurheartj/ehq386 · Cited by 1,807
Self-citation
Consuming fructose-sweetened, not glucose-sweetened, beverages increases visceral adiposity and lipids and decreases insulin sensitivity in overweight/obese humans
Stanhope, K. L., Schwarz, J. M., Keim, N. L., Griffen, S. C., Bremer, A. A., Graham, J. L., Hatcher, B., Cox, C. L., Dyachenko, A., Zhang, W., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37385 · Cited by 1,765
Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality
(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753
Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis
Law, M. R., Wald, N. J., & Rudnicka, A. R. (2003) · BMJ · doi:10.1136/bmj.326.7404.1423 · Cited by 1,720
Untitled work
Graham (2007) · doi:10.1097/01.hjr.0000277983.23934.c9 · Cited by 1,647
Self-citation
Intensive Lipid Lowering with Simvastatin and Ezetimibe in Aortic Stenosis
Rossebø, A. B., Pedersen, T. R., Boman, K., Brudi, P., Chambers, J. B., Egstrup, K., Gerdts, E., Gohlke-Bärwolf, C., Holme, I., Kesäniemi, Y. A., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804602 · Cited by 1,644
Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women
Bansal, S., Buring, J. E., Rifai, N., Mora, S., Sacks, F. M., & Ridker, P. M. (2007) · JAMA · doi:10.1001/jama.298.3.309 · Cited by 1,619
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events
Barter, P., Gotto, A. M., LaRosa, J. C., Maroni, J., Szarek, M., Grundy, S. M., Kastelein, J. J. P., Bittner, V., & Fruchart, J.-C. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa064278 · Cited by 1,610
Effects of the amount and intensity of exercise on plasma lipoproteins
Kraus, W. E., Houmard, J. A., Duscha, B. D., Knetzger, K. J., Wharton, M. B., McCartney, J. S., Bales, C. W., Henes, S., Samsa, G. P., Otvos, J. D., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020194 · Cited by 1,554
High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction<SUBTITLE>The IDEAL Study: A Randomized Controlled Trial</SUBTITLE>
Pedersen, T. R. (2005) · JAMA · doi:10.1001/jama.294.19.2437 · Cited by 1,548
Optimal Diets for Prevention of Coronary Heart Disease
Hu, F. B. (2002) · JAMA · doi:10.1001/jama.288.20.2569 · Cited by 1,503
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Self-citation
Moderate alcohol intake and lower risk of coronary heart disease: meta-analysis of effects on lipids and haemostatic factors
Rimm, E. B., Williams, P., Fosher, K., Criqui, M., & Stampfer, M. J. (1999) · BMJ · doi:10.1136/bmj.319.7224.1523 · Cited by 1,360
Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes: Phase Z of the A to Z Trial
de Lemos, J. A., Blazing, M. A., Wiviott, S. D., Lewis, E. F., Fox, K. A. A., White, H. D., Rouleau, J.-L., Pedersen, T. R., Gardner, L. H., Mukherjee, R., et al. (2004) · JAMA · doi:10.1001/jama.292.11.1307 · Cited by 1,333
EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis
Peters, M. J. L., Symmons, D. P. M., McCarey, D., Dijkmans, B. A. C., Nicola, P., Kvien, T. K., McInnes, I. B., Haentzschel, H., Gonzalez-Gay, M. A., Provan, S., et al. (2010) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2009.113696 · Cited by 1,325
Early Protection Against Sudden Death by n-3 Polyunsaturated Fatty Acids After Myocardial Infarction: Time-Course Analysis of the Results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione
Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M. G., Geraci, E., Levantesi, G., Maggioni, A. P., et al. (2002) · Circulation · doi:10.1161/01.cir.0000014682.14181.f2 · Cited by 1,311
Effect of pravastatin on outcomes after cardiac transplantation
Kobashigawa, J. A., Katznelson, S., Laks, H., Johnson, J. A., Yeatman, L., Wang, X. M., Chia, D., Terasaki, P. I., Sabad, A., Cogert, G. A., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199509073331003 · Cited by 1,301
Secondary Prevention by Raising HDL Cholesterol and Reducing Triglycerides in Patients With Coronary Artery Disease: The Bezafibrate Infarction Prevention (BIP) Study
(2000) · Circulation · doi:10.1161/01.cir.102.1.21 · Cited by 1,273
A Systematic Review of the Evidence Supporting a Causal Link Between Dietary Factors and Coronary Heart Disease
Mente, A., de Koning, L., Shannon, H. S., & Anand, S. S. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.38 · Cited by 1,267
n-3 fatty acids and serum lipoproteins: human studies
Harris, W. (1997) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/65.5.1645s · Cited by 1,243
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management
Chapman, M. J., Ginsberg, H. N., Amarenco, P., Andreotti, F., Borén, J., Catapano, A. L., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr112 · Cited by 1,227
Self-citation
Prevention of coronary heart disease in clinical practice Recommendations of the Second Joint Task Force of European and other Societies on Coronary Prevention
Second Joint Task Force of European (1998) · European Heart Journal · doi:10.1053/euhj.1998.1243 · Cited by 1,131
Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Low-Fat Dietary Pattern and Risk of Cardiovascular Disease: The Women's Health Initiative Randomized Controlled Dietary Modification Trial
Howard, B. V., Van Horn, L., Hsia, J., Manson, J. E., Stefanick, M. L., Wassertheil-Smoller, S., Kuller, L. H., LaCroix, A. Z., Langer, R. D., Lasser, N. L., et al. (2006) · JAMA · doi:10.1001/jama.295.6.655 · Cited by 1,091
Effects of weight reduction on blood lipids and lipoproteins: a meta-analysis
Dattilo, A., & Kris-Etherton, P. (1992) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/56.2.320 · Cited by 1,055
Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial
Ridker, P. M., Danielson, E., Fonseca, F. A., Genest, J., Gotto, A. M., Kastelein, J. J., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60447-5 · Cited by 1,010
Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction
Rasmussen, J. N., Chong, A., & Alter, D. A. (2007) · JAMA · doi:10.1001/jama.297.2.177 · Cited by 975
Effects of Low-Carbohydrate vs Low-Fat Diets on Weight Loss and Cardiovascular Risk Factors: A Meta-analysis of Randomized Controlled Trials
Nordmann, A. J., Nordmann, A., Briel, M., Keller, U., Yancy, W. S., Brehm, B. J., & Bucher, H. C. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.3.285 · Cited by 973
Exercise for overweight or obesity
Shaw, K. A., Gennat, H. C., O'Rourke, P., & Del Mar, C. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003817.pub3 · Cited by 950
n–3 Fatty Acids and Cardiovascular Events after Myocardial Infarction
Kromhout, D., Giltay, E. J., & Geleijnse, J. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003603 · Cited by 936
Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial
Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 934
Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis
Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927
Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial
Holdaas, H., Fellström, B., Jardine, A. G., Holme, I., Nyberg, G., Fauchald, P., Grönhagen-Riska, C., Madsen, S., Neumayer, H.-H., Cole, E., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13638-0 · Cited by 919
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome
Adiels, M., Olofsson, S.-O., Taskinen, M.-R., & Borén, J. (2008) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.160192 · Cited by 820
Self-citation
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries
Kotseva, K., Wood, D., Backer, G. D., Bacquer, D. D., Pyörälä, K., Keil, U., & EUROASPIRE Study Group (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283294b1d · Cited by 812
Self-citation
Omega-6 Fatty Acids and Risk for Cardiovascular Disease: A Science Advisory From the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention
Harris, W. S., Mozaffarian, D., Rimm, E., Kris-Etherton, P., Rudel, L. L., Appel, L. J., Engler, M. M., Engler, M. B., & Sacks, F. (2009) · Circulation · doi:10.1161/circulationaha.108.191627 · Cited by 794
The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
Brugts, J. J., Yetgin, T., Hoeks, S. E., Gotto, A. M., Shepherd, J., Westendorp, R. G. J., de Craen, A. J. M., Knopp, R. H., Nakamura, H., Ridker, P., et al. (2009) · BMJ · doi:10.1136/bmj.b2376 · Cited by 792
Cardiovascular and noncardiovascular mortality among patients starting dialysis
de Jager, D. J. (2009) · JAMA · doi:10.1001/jama.2009.1488 · Cited by 755
Statins in Stroke Prevention and Carotid Atherosclerosis: Systematic Review and Up-to-Date Meta-Analysis
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review
Balk, E. M., Lichtenstein, A. H., Chung, M., Kupelnick, B., Chew, P., & Lau, J. (2006) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.02.012 · Cited by 732
Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes
Laing, S. P., Swerdlow, A. J., Slater, S. D., Burden, A. C., Morris, A., Waugh, N. R., Gatling, W., Bingley, P. J., & Patterson, C. C. (2003) · Diabetologia · doi:10.1007/s00125-003-1116-6 · Cited by 724
Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis
Nicholls, S. J., Tuzcu, E. M., Sipahi, I., Grasso, A. W., Schoenhagen, P., Hu, T., Wolski, K., Crowe, T., Desai, M. Y., Hazen, S. L., et al. (2007) · JAMA · doi:10.1001/jama.297.5.499 · Cited by 724
Fluvastatin for Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention A Randomized Controlled Trial
Serruys, P. W. J. C. (2002) · JAMA · doi:10.1001/jama.287.24.3215 · Cited by 716
Diabetes and mortality following acute coronary syndromes
Donahoe, S. M., Stewart, G. C., McCabe, C. H., Mohanavelu, S., Murphy, S. A., Cannon, C. P., & Antman, E. M. (2007) · JAMA · doi:10.1001/jama.298.7.765 · Cited by 716
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
(2010) · The Lancet · doi:10.1016/s0140-6736(10)60545-4 · Cited by 716
Risks and benefits of omega 3 fats for mortality, cardiovascular disease, and cancer: systematic review
Hooper, L., Thompson, R. L., Harrison, R. A., Summerbell, C. D., Ness, A. R., Moore, H. J., Worthington, H. V., Durrington, P. N., Higgins, J. P. T., Capps, N. E., et al. (2006) · BMJ · doi:10.1136/bmj.38755.366331.2f · Cited by 676
Self-citation
Health effects of trans-fatty acids: experimental and observational evidence
Mozaffarian, D., Aro, A., & Willett, W. C. (2009) · European Journal of Clinical Nutrition · doi:10.1038/sj.ejcn.1602973 · Cited by 662
Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention
Amarenco, P., & Labreuche, J. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70058-4 · Cited by 660
A meta-analysis of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk
Sniderman, A. D., Williams, K., Contois, J. H., Monroe, H. M., McQueen, M. J., de Graaf, J., & Furberg, C. D. (2011) · Circulation: Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.110.959247 · Cited by 659
Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial
Wood, D., Kotseva, K., Connolly, S., Jennings, C., Mead, A., Jones, J., Holden, A., De Bacquer, D., Collier, T., De Backer, G., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60868-5 · Cited by 601
Self-citation
Reduction in cardiovascular events after vascular surgery with atorvastatin: a randomized trial
Durazzo, A. E. S., Machado, F. S., Ikeoka, D. T., De Bernoche, C., Monachini, M. C., Puech-Leão, P., & Caramelli, B. (2004) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2004.01.004 · Cited by 595
Fasting and Nonfasting Lipid Levels: Influence of Normal Food Intake on Lipids, Lipoproteins, Apolipoproteins, and Cardiovascular Risk Prediction
Langsted, A., Freiberg, J. J., & Nordestgaard, B. G. (2008) · Circulation · doi:10.1161/circulationaha.108.804146 · Cited by 588
Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia
Cuchel, M., Bloedon, L. T., Szapary, P. O., Kolansky, D. M., Wolfe, M. L., Sarkis, A., Millar, J. S., Ikewaki, K., Siegelman, E. S., Gregg, R. E., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa061189 · Cited by 580
Effects of Fenofibrate Treatment on Cardiovascular Disease Risk in 9,795 Individuals With Type 2 Diabetes and Various Components of the Metabolic Syndrome
Scott, R., O'Brien, R., Fulcher, G., Pardy, C., d'Emden, M., Tse, D., Taskinen, M.-R., Ehnholm, C., Keech, A., & on behalf of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators (2009) · Diabetes Care · doi:10.2337/dc08-1543 · Cited by 551
Self-citation
Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database
Hippisley‐Cox, J., & Coupland, C. A. C. (2010) · BMJ · doi:10.1136/bmj.c2197 · Cited by 511
Statins for Improving Renal Outcomes
Sandhu, S., Wiebe, N., Fried, L. F., & Tonelli, M. A. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006010012 · Cited by 475
The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia
Fruchart, J.-C., Sacks, F., Hermans, M. P., Assmann, G., Brown, W. V., Ceska, R., Chapman, M. J., Dodson, P. M., Fioretto, P., Ginsberg, H. N., et al. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.10.002 · Cited by 463
Self-citation
Dietary glycemic load assessed by food-frequency questionnaire in relation to plasma high-density-lipoprotein cholesterol and fasting plasma triacylglycerols in postmenopausal women
Liu, S., Manson, J. E., Stampfer, M. J., Holmes, M. D., Hu, F. B., Hankinson, S. E., & Willett, W. C. (2001) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/73.3.560 · Cited by 454
Mechanism of action of niacin
Kamanna, V. S., & Kashyap, M. L. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.029 · Cited by 453
Simvastatin Reduces Graft Vessel Disease and Mortality After Heart Transplantation: A Four-Year Randomized Trial
Wenke, K., Meiser, B., Thiery, J., Nagel, D., von Scheidt, W., Steinbeck, G., Seidel, D., & Reichart, B. (1997) · Circulation · doi:10.1161/01.cir.96.5.1398 · Cited by 444
Atherosclerosis and Coronary Artery Disease
(1996) · Nature Medicine · doi:10.1038/nm0796-822 · Cited by 441
European guidelines on cardiovascular disease prevention in clinical practice Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts)
Backer, G. D., Ambrosioni, E., Broch-Johnsen, K., Brotons, C., Cífková, R., Dallongeville, J., Ebrahim, S. B. J., Færgeman, O., Graham, I. M., Mancia, G., et al. (2003) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/00149831-200308000-00004 · Cited by 440
Self-citation
Value and Limitations of Existing Scores for the Assessment of Cardiovascular Risk
Cooney, M. T., Dudina, A. L., & Graham, I. M. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.07.020 · Cited by 436
Self-citation
Final conclusions and recommendations of the National Lipid Association Statin Safety Assessment Task Force
McKenney, J. M., Davidson, M. H., Jacobson, T. A., & Guyton, J. R. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.02.030 · Cited by 431
Effect of pravastatin on cardiovascular events in older patients with myocardial infarction and cholesterol levels in the average range. Results of the Cholesterol and Recurrent Events (CARE) trial
Lewis, S. J., Moye, L. A., Sacks, F. M., Johnstone, D. E., Timmis, G., Mitchell, J., Limacher, M., Kell, S., Glasser, S. P., Grant, J., et al. (1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-129-9-199811010-00002 · Cited by 427
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study
Neil, A., Cooper, J., Betteridge, J., Capps, N., McDowell, I., Durrington, P., Seed, M., Humphries, S. E., & on behalf of the Simon Broome Familial Hyperlipidaemia Register Group (2008) · European Heart Journal · doi:10.1093/eurheartj/ehn422 · Cited by 425 · cited 2×
“Drug treatment should be rigorous but should be used cautiously in women with childbearing potential.(155) There seems no reason to adopt LDL-C targets for statin treatment different from those in other markedly increased risk patients.”
BackgroundSelf-citation
Primary Prevention of Cardiovascular Mortality and Events With Statin Treatments
Mills, E. J., Rachlis, B., Wu, P., Devereaux, P. J., Arora, P., & Perri, D. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.08.039 · Cited by 423
Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S
Ballantyne, C. M., Olsson, A. G., Cook, T. J., Mercuri, M. F., Pedersen, T. R., & Kjekshus, J. (2001) · Circulation · doi:10.1161/hc5001.100624 · Cited by 416
Self-citation
Safety considerations with fibrate therapy
Davidson, M. H., Armani, A., McKenney, J. M., & Jacobson, T. A. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.016 · Cited by 408
Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin
Jones, P. H., & Davidson, M. H. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.08.076 · Cited by 387
The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease
Kjekshus, J., Pedersen, T. R., Olsson, A. G., Færgeman, O., & Pyörälä, K. (1997) · Journal of Cardiac Failure · doi:10.1016/s1071-9164(97)90022-1 · Cited by 386
Self-citation
Efficacy and tolerability of adding prescription Omega-3 fatty acids 4 g/d to Simvastatin 40 mg/d in hypertriglyceridemic patients: An 8-week, randomized, double-blind, placebo-controlled study
Davidson, M. H., Stein, E. A., Bays, H. E., Maki, K. C., Doyle, R. T., Shalwitz, R. A., Ballantyne, C. M., & Ginsberg, H. N. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.018 · Cited by 385
LDL particle subclasses, LDL particle size, and carotid atherosclerosis in the Multi-Ethnic Study of Atherosclerosis (MESA)
Mora, S., Szklo, M., Otvos, J. D., Greenland, P., Psaty, B. M., Goff, D. C., O’Leary, D. H., Saad, M. F., Tsai, M. Y., & Sharrett, A. R. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.05.007 · Cited by 380
Fluvastatin and Perioperative Events in Patients Undergoing Vascular Surgery
Schouten, O., Boersma, E., Hoeks, S. E., Benner, R., van Urk, H., van Sambeek, M. R. H. M., Verhagen, H. J. M., Khan, N. A., Dunkelgrun, M., Bax, J. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808207 · Cited by 374
Meta-Analysis of the Relationship Between Non–High-Density Lipoprotein Cholesterol Reduction and Coronary Heart Disease Risk
Robinson, J. G., Wang, S., Smith, B. J., & Jacobson, T. A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.10.024 · Cited by 368
Early and Late Benefits of High-Dose Atorvastatin in Patients With Acute Coronary Syndromes
Ray, K. K., Cannon, C. P., McCabe, C. H., Cairns, R., Tonkin, A. M., Sacks, F. M., Jackson, G., & Braunwald, E. (2005) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2005.03.077 · Cited by 356
Use of the Thyroid Hormone Analogue Eprotirome in Statin-Treated Dyslipidemia
Ladenson, P. W., Kristensen, J. D., Ridgway, E. C., OLSSON, A. G., Carlsson, B., Klein, I. L., Baxter, J. D., & Angelin, B. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0905633 · Cited by 338
Prevention of coronary heart disease in clinical practice: recommendations of the task force of the European Society of cardiology, European atherosclerosis Society and European society of Hypertension
Pyörälä, K., DeBacker, G., Graham, I. D., Poole-Wilson, P. A., & Wood, D. A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90200-3 · Cited by 327
Self-citation
Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease
SHARP Collaborative Group (2010) · American Heart Journal · doi:10.1016/j.ahj.2010.08.012 · Cited by 319
Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: Sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)
Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., et al. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.003 · Cited by 316
Efficacy of Atorvastatin Reload in Patients on Chronic Statin Therapy Undergoing Percutaneous Coronary Intervention
Di Sciascio, G., Patti, G., Pasceri, V., Gaspardone, A., Colonna, G., & Montinaro, A. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.05.028 · Cited by 315
Effect of Xuezhikang, an extract from red yeast Chinese rice, on coronary events in a Chinese population with previous myocardial infarction
Lu, Z., Kou, W., Du, B., Wu, Y., Zhao, S., Brusco, O. A., Morgan, J. M., & Capuzzi, D. M. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.056 · Cited by 315
Statins for the primary prevention of cardiovascular disease
Taylor, F. C., Ward, K. J., Moore, T. H., Burke, M., Smith, G. D., Casas, J. P., & Ebrahim, S. B. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub4 · Cited by 315
Effects of dietary fructose on plasma lipids in healthy subjects
Bantle, J. P., Raatz, S. K., Thomas, W. T. B., & Georgopoulos, A. (2000) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.5.1128 · Cited by 312
Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial)
Grundy, S. M., Vega, G. L., Yuan, Z., Battisti, W. P., Brady, W. E., & Palmisano, J. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.10.012 · Cited by 309
Cardiovascular morbidity in psoriatic arthritis
Gladman, D. D., Ang, M., Su, L., Tom, B. D. M., Schentag, C. T., & Farewell, V. T. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2008.094839 · Cited by 304
Report of the national heart, lung, and blood institute workshop on lipoprotein(a) and cardiovascular disease: recent advances and future directions
Marcovina, S. M., Koschinsky, M. L., Albers, J. J., & Skarlatos, S. (2003) · Clinical Chemistry · doi:10.1373/clinchem.2003.023689 · Cited by 288
Contraceptive hormone use and cardiovascular disease
Shufelt, C. L., & Bairey Merz, C. N. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.09.042 · Cited by 287 · cited 1×
“4 mmol/L, more than 160 mg/dL), or with multiple risk factors and in those at high risk of thrombotic events.(165) Oestrogen replacement therapy, despite some favourable effects on the lipid profile, has not been demonstrated to reduce CV risk and cannot be recommended for CV prevention in women.”
Background
Red Yeast Rice for Dyslipidemia in Statin-Intolerant Patients: A Randomized Trial
Becker, D. J., Gordon, R. Y., Halbert, S. C., French, B., Morris, P. B., & Rader, D. J. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-150-12-200906160-00006 · Cited by 275
Reduction of Stroke Events With Pravastatin
Byington, R. P., Davis, B. R., Plehn, J. F., White, H. D., Baker, J., Cobbe, S. M., & Shepherd, J. (2001) · Circulation · doi:10.1161/01.cir.103.3.387 · Cited by 275
Severe hypertriglyceridemia and pancreatitis: presentation and management
Ewald, N., Hardt, P. D., & Kloer, H.-U. (2009) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283319a1d · Cited by 273
Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis
Bruckert, E., Labreuche, J., & Amarenco, P. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.12.023 · Cited by 273
Drug Treatment of Hyperlipidemia in Women
Walsh, J. M. E. (2004) · JAMA · doi:10.1001/jama.291.18.2243 · Cited by 270
Safety considerations with niacin therapy
Guyton, J. R., & Bays, H. E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.11.018 · Cited by 269
Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk
Humphries, S. E., Whittall, R. A., Hubbart, C. S., Maplebeck, S., Cooper, J. A., Soutar, A. K., Naoumova, R., Thompson, G. R., Seed, M., Durrington, P. N., et al. (2006) · Journal of Medical Genetics · doi:10.1136/jmg.2006.038356 · Cited by 267
Self-citation
HDL cholesterol protects against cardiovascular disease in both genders, at all ages and at all levels of risk
Cooney, M. T., Dudina, A., De Bacquer, D., Wilhelmsen, L., Sans, S., Menotti, A., De Backer, G., Jousilahti, P., Keil, U., Thomsen, T., et al. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.041 · Cited by 250 · cited 20×
“A combination of high waist circumference and elevation of TG is a simple and inexpensive screening tool to discriminate people with MetS at high CVD risk for global risk evaluation.95 Since CVD is the major cause of both morbidity and mortality in people with diabetes, the global epidemic of type 2 diabetes foresees…”
BackgroundInfluentialSelf-citation
Effects of High-Dose Modified-Release Nicotinic Acid on Atherosclerosis and Vascular Function
Lee, J. M. S., Robson, M. D., Yu, L.-M., Shirodaria, C. C., Cunnington, C., Kylintireas, I., Digby, J. E., Bannister, T., Handa, A., Wiesmann, F., et al. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.06.036 · Cited by 246 · cited 2×
“A recent meta-analysis suggests that nicotinic acid alone or in combination with statin may add further benefit in stroke prevention.(133)”
BackgroundMethodSelf-citation
Meta-Analysis: The Effect of Statins on Albuminuria
Douglas, K., O’Malley, P. G., & Jackson, J. L. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-2-200607180-00009 · Cited by 246
Familial hypercholesterolaemia: summary of NICE guidance
Wierzbicki, A. S., Humphries, S. E., Minhas, R., & on behalf of the Guideline Development Group (2008) · BMJ · doi:10.1136/bmj.a1095 · Cited by 237
Niacin and fibrates in atherogenic dyslipidemia: pharmacotherapy to reduce cardiovascular risk
Chapman, M. J., Redfern, J. S., McGovern, M. E., & Giral, P. (2010) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2010.01.008 · Cited by 227 · cited 2×
“The latter effect is regarded as the most relevant for the HDL functions.(112)”
BackgroundSelf-citation
Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)
Canner, P. L., Furberg, C. D., Terrin, M. L., & McGovern, M. E. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2004.09.013 · Cited by 226
The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6–HDL and LDL Treatment Strategies in Atherosclerosis)
Villines, T. C., Stanek, E. J., Devine, P. J., Turco, M., Miller, M., Weissman, N. J., Griffen, L., & Taylor, A. J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.03.017 · Cited by 223
Cardiovascular Risk-Estimation Systems in Primary Prevention: Do They Differ? Do They Make a Difference? Can We See the Future?
Cooney, M. T., Dudina, A., D'Agostino, R., & Graham, I. M. (2010) · Circulation · doi:10.1161/circulationaha.109.852756 · Cited by 222
Self-citation
Effect of lifestyle intervention on the occurrence of metabolic syndrome and its components in the Finnish Diabetes Prevention Study
Ilanne-Parikka, P., Eriksson, J. G., Lindström, J., Peltonen, M., Aunola, S., Hämäläinen, H., Keinänen-Kiukaanniemi, S., Laakso, M., Valle, T. T., Lahtela, J., et al. (2008) · Diabetes Care · doi:10.2337/dc07-1117 · Cited by 218
European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV*
Lundgren, J., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W., Reiss, P., et al. (2008) · HIV Medicine · doi:10.1111/j.1468-1293.2007.00534.x · Cited by 210
Lipid-lowering for peripheral arterial disease of the lower limb
Aung, P. P., Maxwell, H., Jepson, R. G., Price, J. F., & Leng, G. C. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000123.pub2 · Cited by 208
Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study)
Ballantyne, C. M., Weiss, R., Moccetti, T., Vogt, A., Eber, B., Sosef, F., & Duffield, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2006.10.022 · Cited by 196
Serum cholesterol response to dietary cholesterol
Keys, A. B. (1984) · American Journal of Clinical Nutrition · doi:10.1093/ajcn/40.2.351 · Cited by 188
Intensive statin therapy and the risk of hospitalization for heart failure after an acute coronary syndrome in the PROVE IT-TIMI 22 Study
Scirica, B. M., Morrow, D. A., Cannon, C. P., Ray, K. K., Sabatine, M. S., Jarolim, P., Shui, A., McCabe, C. H., & Braunwald, E. (2006) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.03.034 · Cited by 181
Relation of atherosclerotic changes in retinal arteries to the extent of coronary artery disease
Tedeschi-Reiner, E., Strozzi, M., Skoric, B., & Reiner, Z. (2005) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.05.070 · Cited by 178
Self-citation
Ten-year risk of cardiovascular incidence related to diabetes, prediabetes, and the metabolic syndrome
Liu, J., Grundy, S. M., Wang, W., Smith, S. C., Lena Vega, G., Wu, Z., Zeng, Z., Wang, W., & Zhao, D. (2007) · American Heart Journal · doi:10.1016/j.ahj.2007.01.003 · Cited by 177 · cited 6×
“Treatment strategies for subjects with type 2 diabetes and metabolic syndrome Lifestyle therapy to improve the atherogenic lipid profile should be recommended to all subjects with type 2 diabetes and MetS.173 Dietary advice should be tailored according to individuals needs.”
BackgroundInfluential
Effect of High-Dose Atorvastatin on Hospitalizations for Heart Failure: Subgroup Analysis of the Treating to New Targets (TNT) Study
Khush, K. K., Waters, D. D., Bittner, V., Deedwania, P. C., Kastelein, J. J. P., Lewis, S. J., & Wenger, N. K. (2007) · Circulation · doi:10.1161/circulationaha.106.625574 · Cited by 172
Effect of Policosanol on Lipid Levels Among Patients With Hypercholesterolemia or Combined Hyperlipidemia
Berthold, H. K., Unverdorben, S., Degenhardt, R., Bulitta, M., & Gouni‐Berthold, I. (2006) · JAMA · doi:10.1001/jama.295.19.2262 · Cited by 170
Basic data concerning associated coronary disease in peripheral vascular patients
Hertzer, N. R. (1987) · Annals of Vascular Surgery · doi:10.1016/s0890-5096(06)61452-0 · Cited by 161
Effect of pravastatin in people with diabetes and chronic kidney disease
Tonelli, M., Keech, A., Shepherd, J., Sacks, F., Tonkin, A., Packard, C., Pfeffer, M., Simes, J., Isles, C., Furberg, C., et al. (2005) · Journal of the American Society of Nephrology · doi:10.1681/asn.2005070779 · Cited by 159
Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV Cohort Study
Glass, T., Ungsedhapand, C., Wolbers, M., Weber, R., Vernazza, P., Rickenbach, M., Furrer, H., Bernasconi, E., Cavassini, M., Hirschel, B., et al. (2006) · HIV Medicine · doi:10.1111/j.1468-1293.2006.00400.x · Cited by 156
Untitled work
Veenkamp (2002) · doi:10.1161/hq0202.104059 · Cited by 152
Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or ezetimibe versus a statin alone (the COMPELL study)
McKenney, J. M., Jones, P. H., Bays, H. E., Knopp, R. H., Kashyap, M. L., Ruoff, G. E., & McGovern, M. E. (2007) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2006.11.037 · Cited by 150
Physicians' perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey
Reiner, Ž., Sonicki, Z., & Tedeschi-Reiner, E. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.09.014 · Cited by 148
Self-citation
Impact of gender in primary prevention of coronary heart disease with statin therapy: a meta-analysis
Petretta, M., Costanzo, P., Perrone-Filardi, P., & Chiariello, M. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.08.001 · Cited by 141
Guar gum and similar soluble fibers in the regulation of cholesterol metabolism: Current understandings and future research priorities
Rideout, T. C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s3512 · Cited by 137
Knowledge and attitudes regarding cardiovascular disease risk and prevention in patients with coronary or peripheral arterial disease
McDermott, M. M., Mandapat, A. L., Moates, A., Albay, M., Chiou, E., Celic, L., & Greenland, P. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.18.2157 · Cited by 135
Alcohol Consumption and Risk for Coronary Heart Disease among Men with Hypertension
Beulens, J. W. J., Rimm, E. B., Ascherio, A., Spiegelman, D. L., Hendriks, H., & Mukamal, K. J. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-146-1-200701020-00004 · Cited by 133
Selecting target conditions for quality of care improvement in vulnerable older adults
Sloss, E. M., Solomon, D. H., Shekelle, P. G., Young, R. T., Saliba, D., MacLean, C. H., Rubenstein, L. Z., Schnelle, J. F., Kamberg, C. J., & Wenger, N. S. (2000) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2000.tb04691.x · Cited by 132
Colesevelam lowers glucose and lipid levels in type 2 diabetes: The clinical evidence
Fonseca, V. A., Handelsman, Y., & Staels, B. (2010) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2009.01181.x · Cited by 130
Effects of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors
MAS, R., CASTANO, G., ILLNAIT, J., FERNANDEZ, L., FERNANDEZ, J., ALEMAN, C., PONTIGAS, V, & LESCAY, M. (1999) · Clinical Pharmacology & Therapeutics · doi:10.1016/s0009-9236(99)70139-6 · Cited by 130
Statin safety: an assessment using an administrative claims database
Cziraky, M. J., Willey, V. J., McKenney, J. M., Kamat, S. A., Fisher, M. D., Guyton, J. R., Jacobson, T. A., & Davidson, M. H. (2006) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2005.12.011 · Cited by 130
Small dense low-density lipoprotein and its role as an independent predictor of cardiovascular disease
Packard, C. J. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000236367.42755.c1 · Cited by 127
Effects of statin therapy on the progression of carotid atherosclerosis: a systematic review and meta-analysis
Kang, S., Wu, Y., & Li, X. (2004) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.08.005 · Cited by 126
Advanced method for the identification of patients with inherited hypercholesterolemia
Defesche, J., Lansberg, P., Umans-Eckenhausen, M., & Kastelein, J. (2004) · Seminars in Vascular Medicine · doi:10.1055/s-2004-822987 · Cited by 123
Nutritional and nutraceutical approaches to dyslipidemia and atherosclerosis prevention: Focus on dietary proteins
Sirtori, C. R., Galli, C., Anderson, J. W., & Arnoldi, A. (2008) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2008.06.019 · Cited by 123
Low glycaemic index diets for coronary heart disease
Kelly, S. A., Frost, G., Whittaker, V., & Summerbell, C. D. (2004) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004467.pub2 · Cited by 122
How much does HDL cholesterol add to risk estimation? A report from the SCORE Investigators
Cooney, M. T., Dudina, A., De Bacquer, D., Fitzgerald, A., Conroy, R., Sans, S., Menotti, A., De Backer, G., Jousilahti, P., Keil, U., et al. (2009) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1097/hjr.0b013e3283213140 · Cited by 121
Self-citation
Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART
Calza, L., Manfredi, R., & Chiodo, F. (2003) · AIDS · doi:10.1097/00002030-200304110-00010 · Cited by 120
Characteristics of the Diet Patterns Tested in the Optimal Macronutrient Intake Trial to Prevent Heart Disease (OmniHeart): Options for a Heart-Healthy Diet
Swain, J. F., McCarron, P. B., Hamilton, E. F., Sacks, F. M., & Appel, L. J. (2008) · Journal of the American Dietetic Association · doi:10.1016/j.jada.2007.10.040 · Cited by 112
Drug Therapy in the Heart Transplant Recipient: Part IV: Drug–Drug Interactions
Page, R. L., Miller, G. G., & Lindenfeld, J. (2005) · Circulation · doi:10.1161/01.cir.0000151805.86933.35 · Cited by 100
Combined therapy in the treatment of dyslipidemia
Reiner, Ž. (2010) · Fundamental & Clinical Pharmacology · doi:10.1111/j.1472-8206.2009.00764.x · Cited by 100
Self-citation
Can statins reduce perioperative morbidity and mortality in patients undergoing non-cardiac vascular surgery?
Paraskevas, K. I., Liapis, C. D., Hamilton, G., & Mikhailidis, D. P. (2006) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2006.03.009 · Cited by 97
Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)
Charlton-Menys, V., Betteridge, D. J., Colhoun, H., Fuller, J., France, M., Hitman, G. A., Livingstone, S. J., Neil, H. A. W., Newman, C. B., Szarek, M., et al. (2009) · Clinical Chemistry · doi:10.1373/clinchem.2008.111401 · Cited by 94
Self-citation
Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes
on behalf of the FIELD study investigators, Taskinen, M.-R., Barter, P. J., Ehnholm, C., Sullivan, D. R., Mann, K., Simes, J., Best, J. D., Hamwood, S., & Keech, A. C. (2010) · Diabetologia · doi:10.1007/s00125-010-1806-9 · Cited by 94
Self-citation
The effect of select nutrients on serum high-density lipoprotein cholesterol and apolipoprotein A-I levels
Mooradian, A. D., Haas, M. J., & Wong, N. C. W. (2006) · Endocrine Reviews · doi:10.1210/er.2005-0013 · Cited by 91
Lipid-Altering Efficacy and Safety of Ezetimibe/Simvastatin Coadministered With Extended-Release Niacin in Patients With Type IIa or Type IIb Hyperlipidemia
Guyton, J. R., Brown, B. G., Fazio, S., Polis, A., Tomassini, J. E., & Tershakovec, A. M. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.03.003 · Cited by 91
A Critical Evaluation of the Role of Soy Protein and Isoflavone Supplementation in the Control of Plasma Cholesterol Concentrations
Dewell, A., Hollenbeck, P. L. W., & Hollenbeck, C. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2350 · Cited by 90
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk
Brown, B. G., & Zhao, X.-Q. (2008) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2008.02.039 · Cited by 84
Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials)
Murphy, S. A., Cannon, C. P., Wiviott, S. D., de Lemos, J. A., Blazing, M. A., McCabe, C. H., Califf, R. M., & Braunwald, E. (2007) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2007.04.053 · Cited by 82
Effect of statins on the progression of bioprosthetic aortic valve degeneration
Antonini-Canterin, F., Zuppiroli, A., Popescu, B. A., Granata, G., Cervesato, E., Piazza, R., Pavan, D., & Nicolosi, G. L. (2003) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2003.08.066 · Cited by 81
Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week multicenter, randomized, double-blind, controlled trial
Huijgen, R., Abbink, E. J., Bruckert, E., Stalenhoef, A. F. H., Imholz, B. P. M., Durrington, P. N., Trip, M. D., Eriksson, M., Visseren, F. L. J., Schaefer, J. R., et al. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.014 · Cited by 80
Self-citation
Pharmacokinetics and pharmacodynamics of combined use of lopinavir/ritonavir and rosuvastatin in HIV-infected patients
Van Der Lee, M., Sankatsing, R., Schippers, E., Vogel, M., Fätkenheuer, G., Van Der Ven, A., Kroon, F., Rockstroh, J., Wyen, C., Bäumer, A., et al. (2007) · Antiviral Therapy · doi:10.1177/135965350701200711 · Cited by 78
Statins: an essential component in the management of carotid artery disease
Paraskevas, K. I., Hamilton, G., & Mikhailidis, D. P. (2007) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2007.03.035 · Cited by 77
Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention
Ordovas, J. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27113e · Cited by 74
Public perceptions of cardiovascular risk factors in Croatia: The PERCRO survey
Reiner, Ž., Sonicki, Z., & Tedeschi-Reiner, E. (2010) · Preventive Medicine · doi:10.1016/j.ypmed.2010.09.015 · Cited by 73
Self-citation
The safety of rosuvastatin in comparison with other statins in over 100 000 statin users in UK primary care
García‐Rodríguez, L. A., Massó-González, E. L., Wallander, M.-A. A., & Johansson, S. (2008) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.1603 · Cited by 65
Non-pharmacological control of plasma cholesterol levels
Poli, A., Marangoni, F., Paoletti, R., Mannarino, E., Lupattelli, G., Notarbartolo, A., Aureli, P., Bernini, F., Cicero, A., Gaddi, A., et al. (2008) · Nutrition, Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2007.10.004 · Cited by 63
Self-citation
Relationships of HDL Cholesterol, ApoA-I, and ApoA-II With Homocysteine and Creatinine in Patients With Type 2 Diabetes Treated With Fenofibrate
Taskinen, M.-R., Sullivan, D. R., Ehnholm, C., Whiting, M., Zannino, D., Simes, R. J., Keech, A. C., & Barter, P. J. (2009) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.108.178228 · Cited by 63
Self-citation
Cardiovascular and cancer mortality in very elderly post-myocardial infarction patients receiving statin treatment
Gränsbo, K., Melander, O., Wallentin, L., Lindbäck, J., Stenestrand, U., Carlsson, J., & Nilsson, J. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.01.013 · Cited by 62
Fibrates in the prevention of cardiovascular disease in patients with type 2 diabetes mellitus--a pooled meta-analysis of randomized placebo-controlled clinical trials
Saha, S. A., & Arora, R. R. (2010) · International Journal of Cardiology · doi:10.1016/j.ijcard.2008.11.211 · Cited by 61
Do lipids, blood pressure, diabetes, and smoking confer equal risk of myocardial infarction in women as in men? The Reykjavik Study
Jonsdottir (2002) · Journal of Cardiovascular Risk · doi:10.1097/00043798-200204000-00001 · Cited by 61
Combination statin-fibrate therapy: safety aspects
Franssen, R., Vergeer, M., Stroes, E. S. G., & Kastelein, J. J. P. (2009) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00917.x · Cited by 60 · cited 1×
“The increased risk for myopathy when combining statins with other fibrates such as fenofibrate, bezafibrate, or ciprofibrate seems to be small.(104,105)”
Background

Research works printed but not linked: 4

Abumweis SS, Barake R, Jones PJ. Plant sterols/stanols as cholesterol lowering agents: a meta-analysis of randomized controlled trials. Food Nutr Res 2008;52, doi:10.3402/fnr.v52io.1811. · DOI
2005, Process for the assessment of scientific support for claims on foods: consensus on criteria, Eur J Nutr, 44, I/5
Poulter, 1999, The impact of micronized fenofibrate on lipid subfractions and on reaching HDL-target levels in 7,098 patients with dyslipidaemia, Br J Cardiol, 6, 682
DeMott K, Nherera L, Shaw EJ, Minhas R, Humphries SE, Kathoria M, Ritchie G, Nunes V, Davies D, Lee P, McDowell I, Neil A, Qureshi N, Rowlands P, Seed M, Stracey H, Thorogood M, Watson M. Clinical guidelines and evidence review for familial hypercholesterolaemia: the identification and management of adults and children with familial hypercholesterolaemia. London: National Collaborating Centre for Primary Care and Royal College of General Practitioners; 2008.

Sorted by citations

European guidelines on cardiovascular disease prevention in clinical practice: executive summary
Graham, I., Atar, D., Borch‐Johnsen, K., Boysen, G., Burell, G. K., Cífková, R., Dallongeville, J., Backer, G. D., Ebrahim, S. B. J., Gjelsvik, B., et al. (2007) · European Heart Journal · doi:10.1093/eurheartj/ehm316 · Cited by 3,865
Self-citation
ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
Authors Task Force Members, Rydén, L., Grant, P. J., Anker, S. D., Berne, C., Cosentino, F., Danchin, N., Deaton, C., Escaned, J., Hammes, H., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,994
Self-citation
Effects of extended-release niacin with laropiprant in high-risk patients
The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668
Dyslipidemia in obesity: Mechanisms and potential targets
Klop, B., Elte, J., & Cabezas, M. (2013) · Nutrients · doi:10.3390/nu5041218 · Cited by 1,665
Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017
Kinoshita, M., Yokote, K., Arai, H., Iida, M., Ishigaki, Y., Ishibashi, S., Umemoto, S., Egusa, G., Ohmura, H., Okamura, T., et al. (2018) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.gl2017 · Cited by 813

See all 192

Authors: Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., Erdine, S., Halcox, J., Hobbs, R., Kjekshus, J., Perrone Filardi, P., Riccardi, G., Storey, R. F., & Wood, D.
Corresponding author: Catapano, Alberico L.
Reiner, Željko
ORCID: Catapano, Alberico L.
Reiner, Željko
Graham, Ian
Taskinen, Marja-Riitta
Wiklund, Olov
Agewall, Stefan
Chapman, M. John
Durrington, Paul
Erdine, Serap
Halcox, Julian
Hobbs, Richard
Kjekshus, John
Storey, Robert F.
Wood, David
Venue: Atherosclerosis
Publisher: Elsevier BV
Published: 2011-07
Volume: 217
Pages: 1-44
ISSN: 0021-9150 (ISSN-L)
DOI: 10.1016/j.atherosclerosis.2011.06.012
OpenAlex: W4210968492
Cited by: 192
References: 222
Citations by year: 2026: 3 · 2025: 1 · 2023: 7 · 2022: 12 · 2021: 11 · 2020: 11 · 2019: 6 · 2018: 8 · 2017: 13 · 2016: 29 · 2015: 27 · 2014: 10 · 2013: 34 · 2012: 16
FWCI: 3.63
Type: journal article
Language: en
Open access: closed
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: Atherosclerosis (publishedVersion)
PubMed (publishedVersion)
ORBi (University of Liège) (submittedVersion)
Topics: Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Clinical practice guidelines implementation
Keywords: dyslipidemia, dyslipidemia management, lipid-lowering therapy, cardiovascular risk, risk-benefit assessment, clinical guidelines
MeSH terms: Adolescent, Adult, Aged, Cardiology, Cardiovascular Diseases, Child, Cholesterol, Clinical Trials as Topic, Europe, Female, Genotype, Humans, Life Style, Lipids, Lipoproteins, Male, Middle Aged, Societies, Medical, Practice Guidelines as Topic, Dyslipidemias, Atherosclerosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

ESC/EAS Guidelines for the management of dyslipidaemias

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks